Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).

Katyayini Aribindi Gabrielle Y Liu Timothy E Albertson

Published in: Expert review of clinical pharmacology (2024)

New drug development has the potential to expand the treatment options available in the treatment of IPF patients. It is expected that the adverse drug effect profiles will be more favorable than current agents. It is further anticipated that these new agents or combinations of agents will arrest the fibrosis, not just slow the fibrotic process.

Keyphrases

idiopathic pulmonary fibrosis
adverse drug
interstitial lung disease
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
combination therapy
cell cycle
patient reported